文献速递乳腺癌

NeoALTTO研究生存结局更新:HER2阳性早期乳腺癌新辅助双靶向治疗

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
PubMed 文献 · Eur J Cancer · 2019-08-01

NeoALTTO随机III期试验更新随访6.7年结果,评估拉帕替尼联合曲妥珠单抗对比单药的EFS和OS,并分析pCR与长期生存关系。结果显示双靶向未显著改善EFS/OS,但达到pCR者6年EFS和OS显著更优。

要点

  • 双靶向联合紫杉醇未显著改善6年EFS或OS。
  • 达到pCR者6年EFS和OS显著优于未达pCR者。
  • 激素受体阴性亚组中pCR与生存获益同样显著。

核心结论

  • 在HER2阳性早期乳腺癌中,达到pCR与更好的长期EFS和OS相关。
  • 拉帕替尼联合曲妥珠单抗对比单药未显著改善EFS或OS。

研究设计与样本

  • 患者随机接受拉帕替尼1500 mg/天(n=154)、曲妥珠单抗(n=149)或拉帕替尼1000 mg/天联合曲妥珠单抗(n=152)治疗6周,随后联合每周紫杉醇12次,术后接受3周期氟尿嘧啶、表柔比星和环磷酰胺。
  • 主要终点为pCR(ypT0/is ypN0),次要终点为EFS和OS。

主要发现

  • 里程碑分析中,达到pCR者对比未达pCR者,总体人群6年EFS为77% vs 65%,OS为89% vs 77%;激素受体阴性队列中同样显著。

临床怎么用

  • pCR可作为HER2阳性早期乳腺癌长期生存的预后指标。
  • 双靶向联合方案未显示显著生存优势,临床决策需综合考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lapatinib (L) plus trastuzumab (T) with weekly paclitaxel significantly increased the pathologic complete response (pCR) rate compared with the anti-human epidermal growth factor receptor 2 (HER2) agent alone plus paclitaxel. The event-free survival (EFS) and overall survival (OS) by the treatment arms L + T vs. T and L vs. T and the relationship between pCR and EFS/OS both in the whole study population and according to hormone receptor-negative and hormone receptor-positive cohorts after a median follow-up of 6.7 years were assessed. PATIENTS AND METHODS: Four hundred fifty-five patients with HER2-positive early breast cancer randomly received L 1500 mg/day (n = 154), T (common dose, n = 149) or L 1000 mg/day plus T (n = 152) for 6 weeks, followed by the assigned anti-HER2 treatment combined with paclitaxel weekly × 12. After surgery, patients received 3 cycles of fluorouracil, epirubicin and cyclophosphamide. The primary end-point was pCR (ypT0/is; for current analysis, it is ypT0/is ypN0), and the secondary end-points were EFS and OS. RESULTS: Six-year EFS rates were 67%, 67% and 74% with L, T and L + T, respectively (L vs T: hazard ratio [HR], 0.98 [95% confidence interval {CI}, 0.64-1.51; P = .93]; L + T vs T: HR, 0.81 [95% CI, 0.52-1.26; P = .35]). Six-Year OS rates were 82%, 79% and 85% for L, T and L + T, respectively (L vs T: HR, 0.85 [95% CI, 0.49-1.46; P = .56]; L + T vs T: HR, 0.72 [95% CI, 0.41-1.27; P = .26]). In landmark analyses, patients with a pCR had a significantly higher 6-year EFS (77% and 65%) and OS (89% and 77%) compared with those without a pCR for both overall and the hormone receptor-negative cohort. CONCLUSION: Achieving a pCR is important in HER2-positive disease and translates into better long-term outcome with regard to EFS and OS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Huober J, Holmes E, Baselga J, et al. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer. 2019. PMID: 31377477. doi:10.1016/j.ejca.2019.04.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。